Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

@article{Pellegrin2008VirologicalRT,
  title={Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).},
  author={Isabelle Pellegrin and Linda Wittkop and Laurence Morand Joubert and Didier Neau and Diane Bollens and Mojgan Bonarek and P O Girard and H{\'e}rv{\'e} Fleury and B. N. Winters and Marie-Claude Saux and Jean-Luc J. Pellegrin and Rodolphe Thi{\'e}baut and Dominique Breilh},
  journal={Antiviral therapy},
  year={2008},
  volume={13 2},
  pages={271-9}
}
BACKGROUND We assessed the association of baseline HIV-1 mutations, phenotypic sensitivity and pharmacokinetics with virological failure (VF) at week 12 (W12) after onset of a darunavir/ritonavir (DRV/r)-based regimen in a cohort of 67 antiretroviral-experienced HIV-patients failing on highly active antiretroviral therapy (HAART). METHODS VF was defined as HIV RNA >2.3 log10copies/ml at W12. HIV reverse transcriptase and protease sequencing was performed at WO; mutations with a P-value <0.25… CONTINUE READING